Last reviewed · How we verify
NCT04220853
Changes in Nasal Airflow Parameters After Septoplasty and Turbinoplasty
NA trial testing Rhinomanometry in patients after septoplasty and/or turbinoplasty in Nasal Obstruction in 30 participants. Completed in 31 October 2022.
30 September 2022
Quick facts
| Lead sponsor | University Hospital Ostrava |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 30 |
| Start date | 1 October 2019 |
| Primary completion | 30 September 2022 |
| Estimated completion | 31 October 2022 |
| Sites | 1 location across Czechia |
Drugs / interventions tested
- Rhinomanometry in patients after septoplasty and/or turbinoplasty
- Acoustic rhinometry in patients after septoplasty and/or turbinoplasty
Conditions studied
- Nasal Obstruction — all drugs for Nasal Obstruction →
- Nasal Septum; Deviation — all drugs for Nasal Septum; Deviation →
- Nasal Mucosa Hypertrophy — all drugs for Nasal Mucosa Hypertrophy →
Sponsor
University Hospital Ostrava
Who can join
Adults 18 to 70, any sex, with Nasal Obstruction or Nasal Septum; Deviation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pathological-anatomical changes in the nasal cavity (nasal septum/perforation, mucosal hypertrophy) negatively affect nasal airflow, increase resistance - cause nasal obstruction and are often an indication for surgery. The aim of the study is to examine nasal airflow parameters after septoplasty and turbinoplasty .
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04220853
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Nasal Obstruction
Currently open trials in the same condition.
- NCT06580210 — Performance and Safety Assessment of the Mechanical Decongestant Seawater Spray Enriched With Essential Oils From Labora · recruiting
- NCT06830109 — Nasal Obstruction With Oxymetazoline and Corticosteroids · Phase 2 · recruiting
- NCT06670261 — Diagnosis of Respiratory Disorders by the Numerical Modeling. · recruiting
- NCT05494346 — Safety and Performance Assessment of the Decongestant Seawater Spray Pocket Valve Enriched With Essential Oils in Patien · NA · recruiting
- NCT05920330 — Nasal Obstruction and Olfactory Losses · NA · recruiting
Other University Hospital Ostrava trials
Trials by the same sponsor.
- NCT07177183 — Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning Failure · NA · recruiting
- NCT07374289 — On Scene ECPR in Ostrava · NA · recruiting
- NCT07041086 — Prehospital ECPR in Moravia Silesia Region · recruiting
- NCT07009652 — Optimization of Transport and Use of a Mobile ECMO Team in Patients With Sudden Cardiac Arrest in the Moravian-Silesian · recruiting
- NCT06921746 — Changes in the Urinary Microbiome and Metabolome During Treatment of the Overactive Bladder in Female Patients · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04220853 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital Ostrava
- Last refreshed: 7 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04220853.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing